MYCOF (Noveris Health Sciences) PB Ratio: (As of Jul. 06, 2026)


MYCOF Noveris Health Sciences Inc MYCOF
23 GF Score
Price $2.00
GF Value $0.52
Valuation Significantly Overvalued
View Full Analysis

What is Noveris Health Sciences PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-06), Noveris Health Sciences's share price is $2.00. Noveris Health Sciences's Book Value per Share for the quarter that ended in Mar. 2026 was $-0.03. Hence, Noveris Health Sciences's PB Ratio of today is .

The historical rank and industry rank for Noveris Health Sciences's PB Ratio or its related term are showing as below:

During the past 13 years, Noveris Health Sciences's highest PB Ratio was 337.51. The lowest was 0.20. And the median was 4.92.

MYCOF's PB Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.93
* Ranked among companies with meaningful PB Ratio only.

During the past 3 years, the average Book Value Per Share Growth Rate was -32.90% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Noveris Health Sciences was -32.90% per year. The lowest was -56.90% per year. And the median was -54.20% per year.

Back to Basics: PB Ratio


Noveris Health Sciences  (OTCPK:MYCOF) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Noveris Health Sciences PB Ratio Related Terms


Noveris Health Sciences PB Ratio Historical Data

* Premium members only.

The historical data trend for Noveris Health Sciences's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Noveris Health Sciences PB Ratio Chart

Noveris Health Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 173.60 0.00 0.00 0.00 0.00

Noveris Health Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MYCOF vs ZTS, UTHR: PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Noveris Health Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Noveris Health Sciences PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Noveris Health Sciences's PB Ratio distribution charts can be found below:

* The bar in red indicates where Noveris Health Sciences's PB Ratio falls into.


MYCOF
23GF Score
Noveris Health Sciences Inc MYCOF
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Noveris Health Sciences PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Noveris Health Sciences's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2026)
=2.00/-0.028
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Is Noveris Health Sciences (MYCOF) Overvalued in 2026?

Based on GuruFocus' analysis, Noveris Health Sciences stock appears to be overvalued. The current stock price of $2.00 is trading 284.6% above its estimated GF Value™ of $0.52. GuruFocus considers Noveris Health Sciences to be Significantly Overvalued.

Key valuation signals for MYCOF:

  • PB Ratio:
  • GF Value™: $0.52 vs. price of $2.00 (284.6% above fair value)
  • GF Score™: 23/100

No single metric tells the full story. See the MYCOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Noveris Health Sciences Business Description

Other Exchanges 0NF1:GermanyNVRS:Canada
Address 1890 - 1075 West Georgia Street, Suite 810, Vancouver, BC, CAN, V6E 3C9
Noveris Health Sciences Inc is a biotech and life sciences company dedicated to developing and commercializing solutions for treating mental health problems and enhancing vitality. The company has a portfolio of patents it is seeking to commercialize, and is exploring opportunities in the stem cell industry. It is developing the next generation of medications and therapies to address mental health disorders such as nicotine addiction and post-traumatic stress disorder (PTSD).
23GF Score

Get the complete analysis for MYCOF

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.00
Price
$0.52
GF Value